Bezlotoxumab

Identification

Name
Bezlotoxumab
Accession Number
DB13140
Description

Bezlotoxumab is a human monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. Used to reduce the recurrence of Clostridium difficle infection in adults receiving antibiotic therapy to treat C. difficile infection and high risk of recurrence.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Bezlotoxumab
External IDs
  • MBL-CDB1
  • MDX-1388
  • MK-6072

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

Prevents recurrence of Clostridium difficile infection in people 18 years or older who are either currently receiving treatment for C. difficile infection or have a high risk of recurrence.

Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Bezlotoxumab binds to C.difficile toxin B, a virulence factor common to practically all C.difficile, which prevents the bacteria from infecting host cells. Bezlotoxumab binds two epitopes of toxin B, via two Fab regions, which partially blocks the carbohydrate binding pockets of the toxin resulting in the prevention of toxin B from binding to host cells.

Mechanism of action

A single molecule of bezlotoxumab neutralizes Toxin B by binding its two Fab regions to two epitopes within the N-terminal half of the Toxin B CROP domain, partially blocking the carbohydrate binding pockets of the toxin and preventing toxin binding to host cells.

TargetActionsOrganism
AClostridium difficile Toxin B
antibody
Peptoclostridium difficile
Absorption

Not absorbed since give IV

Volume of distribution

7.33L

Protein binding

Binds to C.difficile virulence factor toxin B which prevents its action on host cells.

Metabolism

Catabolism

Route of elimination

Catabolism

Half-life

19 Days

Clearance

0.317 L/day

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

No data available on overdosage.

Affected organisms
  • Peptoclostridium difficile
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Bezlotoxumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Bezlotoxumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bezlotoxumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Bezlotoxumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Bezlotoxumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Bezlotoxumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bezlotoxumab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Asfotase alfa is combined with Bezlotoxumab.
AtezolizumabThe risk or severity of adverse effects can be increased when Atezolizumab is combined with Bezlotoxumab.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ZinplavaInjection, solution, concentrate25 mg/mlIntravenousMerck Sharp & Dohme B.V.2020-12-18Not applicableEU flag
ZinplavaInjection, solution25 mg/1mLIntravenousMerck Sharp & Dohme Corp.2016-10-21Not applicableUS flag

Categories

ATC Codes
J06BB21 — Bezlotoxumab
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
4H5YMK1H2E
CAS number
1246264-45-8

References

General References
  1. Orth P, Xiao L, Hernandez LD, Reichert P, Sheth PR, Beaumont M, Yang X, Murgolo N, Ermakov G, DiNunzio E, Racine F, Karczewski J, Secore S, Ingram RN, Mayhood T, Strickland C, Therien AG: Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem. 2014 Jun 27;289(26):18008-21. doi: 10.1074/jbc.M114.560748. Epub 2014 May 12. [PubMed:24821719]
  2. Zhang Z, Chen X, Hernandez LD, Lipari P, Flattery A, Chen SC, Kramer S, Polishook JD, Racine F, Cape H, Kelly CP, Therien AG: Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection. Infect Immun. 2015 Jan;83(1):405-16. doi: 10.1128/IAI.02550-14. Epub 2014 Nov 10. [PubMed:25385797]
  3. Ghetie V, Ward ES: Transcytosis and catabolism of antibody. Immunol Res. 2002;25(2):97-113. [PubMed:11999172]
  4. FDA Monograph for Zinplava [Link]
PubChem Substance
347911429
RxNav
1855048
Wikipedia
Bezlotoxumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingPreventionClostridium difficile infection recurrence1
4RecruitingPreventionC. Diff. Infections / Crohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Ulcerative Colitis1
4RecruitingPreventionClostridium Difficile1
4RecruitingTreatmentClostridia Difficile Colitis / Clostridium; Sepsis1
4RecruitingTreatmentClostridium difficile infection recurrence1
3CompletedTreatmentClostridium Difficile Infection (CDI)2
3RecruitingPreventionClostridium Difficile Infection (CDI)1
2CompletedTreatmentClostridium Infections1
2RecruitingTreatmentClostridium Difficile Infection (CDI) / Inflammatory Bowel Diseases (IBD)1
Not AvailableEnrolling by InvitationNot AvailableClostridium Difficile Infection (CDI) / Clostridium difficile infection recurrence1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntravenous25 mg/1mL
Injection, solution, concentrateIntravenous25 mg/ml
Injection, solution, concentrateIntravenous; Parenteral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Peptoclostridium difficile
Pharmacological action
Yes
Actions
Antibody
General Function
Glucosyltransferase activity
Specific Function
Cytotoxin.
Gene Name
toxB
Uniprot ID
P18177
Uniprot Name
Toxin B
Molecular Weight
269709.285 Da

Drug created on November 02, 2016 18:42 / Updated on February 21, 2021 18:54